As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.
The real-time PCR test was developed by Thermo Fisher Scientific and validated by Aeon, and detects 34 different pathogens from vaginal swabs.
Researchers sequenced dozens of Treponema pallidum isolates associated with syphilis, yaws, or bejel to look at the emergence of pandemic syphilis.
The new women's health and STI tests for the BD Max platform are part of a small, focused panel approach which the firm believes will resonate with physicians and labs.
The firm plans to submit the Mycoplasma genitalium test to the FDA in 2017 and has entered an agreement with the CDC for test evaluation.
The test detects chlamydia, gonorrhea, and trichomonas from a single patient sample.
The antibiotic-resistant Mycoplasma genitalium test would be the first on the market for a pathogen with increasing evidence for adverse outcomes.
Under the agreement, Goffin will distribute SpeeDx's PlexPCR and ResistancePlus multiplex real-time PCR product lines in Benelux.
Evaluations of the test, which takes about 30 minutes to perform, demonstrated performance equivalent to a gold standard lab-based test.
The Australian firm provided an update on its in vitro diagnostics business, noting that it has also rebranded its core technologies and continues to license them.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.